Maravai Lifesciences Holdings Inc (MRVI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 4:15 PM ET
Maravai Lifesciences Holdings Inc (MRVI) Statistics
Maravai Lifesciences Holdings (MRVI) has a market cap of $1.96B and an enterprise value of $2.03B. It kept -54.00% of revenue as net income over the last 12 months. Its share count is up 3.03% from a year earlier.
Total Valuation
Enterprise value is 3.78% above the market cap, as debt exceeds cash.
| Market Cap | $1.96B |
|---|---|
| Enterprise Value | $2.03B |
| Latest price (Nov 17, 2026) | $7.28 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.1x and 5.5x. Its year-end P/S ranged from 2.1x to 9.5x from 2020 to 2025.
| P/S Ratio | 5.1x |
|---|---|
| Forward P/S | 9.1x |
| P/B Ratio | 5.5x |
Price Statistics
The stock is up 100.00% over 52 weeks and trades 1.62% below its 50-day average.
| Beta (1Y) | 1.65 |
|---|---|
| 52-Week Change | +100.00% |
| 1-Month Change | +4.15% |
| 3-Month Change | +0.83% |
| 6-Month Change | +72.51% |
| 5-Year Change | -81.53% |
| Total Return (1Y) | +100.00% |
| Total Return (3Y CAGR) | +13.19% |
| Total Return (5Y CAGR) | -28.01% |
| Return vs SPY (1Y) | +89.55% |
| Max Drawdown (1Y) | -29.60% |
| Max Drawdown (3Y) | -84.83% |
| Sharpe Ratio (1Y) | 1.05 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $7.40 |
| 200-Day Average | $5.47 |
| 52-Week Range | $2.80 to $9.42 |
| RSI (14 Days) | 46.7 |
| Average Volume (20 Days) | 2.19M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.66x current liabilities, and total debt is 0.75x shareholder equity.
| Current Ratio | 4.66x |
|---|---|
| Quick Ratio | 3.35x |
| Debt / Equity | 0.75x |
| Interest Coverage | 13.86x |
Returns and Efficiency
Return on invested capital is -28.26% over the last 12 months, against a 5-year average of 13.87%.
| Return on Equity (ROE) | -58.72% |
|---|---|
| Return on Assets (ROA) | -19.17% |
| Return on Invested Capital (ROIC) | -28.26% |
| Return on Capital Employed (ROCE) | -17.16% |
| ROE (5Y Average) | 3.41% |
| ROA (5Y Average) | -3.81% |
| ROIC (5Y Average) | 13.87% |
| Asset Turnover | 0.29x |
| Inventory Turnover | 3.07x |
| Receivables Turnover | 7.49x |
| Cash Conversion Cycle | 148 days |
Scores
MRVI has an Altman Z-Score of 2.52, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.52 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $213.00M over the last 12 months is up 10.68% from the 12 months before.
| Revenue | $213.00M |
|---|---|
| Revenue Growth (YoY) | +10.68% |
| Gross Profit | $83.39M |
| Operating Income | -$96.66M |
| Pretax Income | -$115.41M |
| Net Income | -$115.02M |
| EBITDA | -$41.91M |
| EBIT | -$97.28M |
| Reported EPS (TTM) | -$0.18 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 32.64% of the $600.07M in total assets.
| Cash and Equivalents | $73.02M |
|---|---|
| Total Debt | $147.18M |
| Net Debt | $74.16M |
| Net Debt Per Share | $0.50 |
| Working Capital | $120.94M |
| Shareholder Equity | $195.89M |
| Book Value Per Share | $1.31 |
| Tangible Book Value | -$64.51M |
| Total Assets | $600.07M |
| Total Liabilities | $259.90M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $7.44M of capital spending, operating cash flow left -$12.54M of free cash flow.
| Operating Cash Flow | -$5.10M |
|---|---|
| Capital Expenditures | $7.44M |
| Free Cash Flow | -$12.54M |
| FCF Per Share | -$0.08 |
| Depreciation and Amortization | $55.37M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -45.38%, against a 5-year average of -16.67%.
| Gross Margin | 39.15% |
|---|---|
| Operating Margin | -45.38% |
| Pretax Margin | -54.19% |
| Net Margin | -54.00% |
| EBITDA Margin | -19.68% |
| EBIT Margin | -45.67% |
| FCF Margin | -5.89% |
| Gross Margin (5Y Average) | 54.38% |
| Operating Margin (5Y Average) | -16.67% |
| Net Margin (5Y Average) | -31.60% |
Growth
Revenue fell 40.53% a year over 3 years.
| Revenue Growth (3Y CAGR) | -40.53% |
|---|---|
| Revenue Growth (5Y CAGR) | -8.15% |
| Book Value Per Share Growth (2Y CAGR) | -31.87% |
Dividends and Yields
MRVI does not pay a dividend. Its free cash flow yield is -1.16%.
| FCF Yield | -1.16% |
|---|---|
| Buyback Yield | 0.12% |
| Shareholder Yield | 0.12% |
Peer Position
Against 8 similar companies, MRVI has the 5th highest P/S.
P/S RatioPeer median 4.2x
ROICPeer median -48.17%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +19.79%
| P/S Ratio | 5.1x vs 4.2x median |
|---|---|
| ROIC | -28.26% vs -48.17% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +10.68% vs +19.79% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.95% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.95% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About MRVI
What is MRVI's market cap?
Maravai Lifesciences Holdings has a market cap of $1.96B. Its enterprise value, which adds debt and subtracts cash, is $2.03B.
How many shares of MRVI are outstanding?
Maravai Lifesciences Holdings has 149.07M shares outstanding. The count is up 3.03% from a year earlier.
Does MRVI pay a dividend?
No. Maravai Lifesciences Holdings does not pay a dividend.
How much debt does MRVI have?
Maravai Lifesciences Holdings has $147.18M of total debt and $73.02M of cash and equivalents, a net debt position of $74.16M.
MRVI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors